Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rituximab trial in ankylosing spondylitis with extension re-treatment
2006-002306-64Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in ankylosing spondylitis (AS), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: ASAS 20 response at week 24 and study end and ASAS 20 response at week R-24 in extension re-treatment. Started Oct 2006; status: completed.
02
Drugs
rituximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2006-002306-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002306-64.